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Hematological traits such as hemoglobin concentration and white blood cell count are important 
clinical measurements, and are used as biomarkers in medicine to inform diagnosis and 
prognosis.   Previous genetic association studies have identified hundreds of loci that impact 
quantitative blood cell traits, but have not yet fully characterized the heritable component of variation 
between individuals.  In a recent report in Nature Genetics, Drs. Paul Auer and Alexander Reiner 
and colleagues in the Public Health Sciences Division used new genotyping arrays to identify 
several rare mutations in protein-coding regions of the genome that affect blood cell traits.  These 
findings demonstrate how performing exome-wide genotyping on large numbers of individuals is an 
effective approach for identifying novel variants that contribute to complex traits, and can 
complement genome-wide association studies. 
To investigate the impact of rare variants on blood traits, the researchers used an exome array to 
genotype roughly 31,000 participants from three collaborating studies.  These new assays target 
protein-coding variants in the genome that are rare (minor allele frequency < 0.1%) or low-frequency 
(minor allele frequency between 0.1 and 1%), rather than the more common variants targeted by 
other genotyping platforms.  These genotypes were then analyzed for their association with four 
blood cell phenotypes: hemoglobin concentration, hematocrit levels, white blood cell count, and 
platelet count.   
Using this approach, the authors were also able to identify missense or splice-site variants in several 
key hematopoiesis regulators associated with blood cell traits.  These gene variants were associated 
with platelet count (TUBB1, SH2B3, and JAK2), hematocrit levels and hemoglobin concentration 
(EPO and HBB), and white blood cell count (CXCR2).  Said co-senior author Reiner, "our findings 
highlight the contribution of rare and low-frequency coding variants of key genes involved in the 
regulation of hematopoiesis in contributing to the inter-individual differences in circulating blood cell 
counts in large cohorts of apparently hematologically healthy individuals."   
Of these findings, the novel association between the CXCR2 gene and white blood cell count is of 
particular interest because it required the use of gene-based tests in order to be identified.  As the 
association is driven mainly by three independent low-frequency missense variants, this relationship 
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had not been detected in previous genome-wide studies.  This emphasizes the relevance of gene-
based tests as a tool to evaluate rare variants for their contribution to phenotypic variation.   
To further support this new relationship, the researchers also looked at sequence data from families 
with rare, Mendelian congenital hematologic disorders.  In doing so, they identified a CXCR2 
frameshift mutation that abolished ligand-induced CXCR2 signal transduction and chemotaxis in a 
pedigree with congenital neutropenia.  By converging these two lines of evidence, said co-senior 
author Reiner, "we were able to identify causal missense variants in the chemokine receptor CXCR2 
which lead to lower circulating white blood cell and neutrophil counts by inhibiting neutrophil release 
from the bone marrow."   
To follow-up these findings, the authors are planning to continue bringing together and leveraging 
multiple lines of evidence.  Said Reiner, "an important next step will be to integrate the new blood 
cell count-associated genetic loci with available blood cell lineage-specific human transcriptomic, 
functional genomic, and epigenomic datasets."  Utilizing these multiple resources should then allow 
the authors "to functionally characterize the mechanism by which specific variants regulate 
hematopoiesis in humans, which should improve the clinical translatability of these findings."  For 
example, identifying such variants could have potential implications for diagnostic screening and 
drug development for a variety of hematological and inflammatory disorders, such as lung disease 
and stroke.   
Other PHS investigators contributing to this project were Drs. Chris Carlson, Charles Kooperberg, 
Ulrike Peters, and Li Hsu, as well as Ms. Ursula Schick and Mr. Jeff Haessler. 
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Image provided by Dr. Alex Reiner 
Rare and low-frequency missense variants in the CXCR2 gene are associated with lower white 
blood cell count. The vertical lines represent the mean white blood cell count in each of the three 
participating studies, while the color-coded circles provide the white blood cell count for participants 
that carry the variants. Circles are sized according to their minor allele frequency within that study. 
For one variant (rs228413), there was one MHI participant that is homozygous for the rare allele 
(represented by a star). Participating in the study were the Montreal Heart Institute Biobank (MHI), 
the Women’s Health Initiative (WHI), and the Study of Health in Pomerania (SHIP). 
 
